Nuvalent, Inc. (NUVL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$159.7M
Cash & Equivalents
$92.4M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$9,788M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-18 | Pdufa | — |
| 2027-01-01 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | PHASE3 | Recruiting | 450 |
| NCT05118789 | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (A... | PHASE2 | Recruiting | 359 |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | PHASE1 | Recruiting | 200 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-09 | 8-K | Nuvalent, Inc. (NUVL) (CIK 0001861560) - EX-99.1 | EDGAR |